- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12. | Tenaya Therapeutics: Canaccord senkt Kursziel auf 5 US-Dollar, bestätigt aber 'Buy'-Rating | 18 | Investing.com Deutsch | ||
| TENAYA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.12. | Tenaya Therapeutics stock price target lowered to $5 at Canaccord | 4 | Investing.com | ||
| 12.12. | Tenaya Stock Plunges After $60 Million Equity Offering | 7 | Benzinga.com | ||
| 12.12. | Tenaya Therapeutics platziert Kapitalerhöhung über 60 Millionen US-Dollar | 28 | Investing.com Deutsch | ||
| 12.12. | Tenaya Therapeutics prices $60 million public offering of stock and warrants | 6 | Investing.com | ||
| 12.12. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Pricing of Public Offering | 21 | GlobeNewswire (USA) | ||
| 11.12. | Tenaya Therapeutics kündigt Angebot von Aktien und Optionsscheinen an | 12 | Investing.com Deutsch | ||
| 11.12. | FDA hebt klinischen Stopp für Gentherapie-Studie von Tenaya zu Herzerkrankungen auf | 22 | Investing.com Deutsch | ||
| 11.12. | FDA lifts clinical hold on Tenaya's heart disease gene therapy trial | 8 | Investing.com | ||
| 11.12. | Tenaya Therapeutics plans to offer stock and warrant units | 1 | Investing.com | ||
| 11.12. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Proposed Public Offering | 3 | GlobeNewswire (USA) | ||
| 11.12. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC | 115 | GlobeNewswire (Europe) | TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8Clinically Meaningful Reductions in Arrhythmia Burden... ► Artikel lesen | |
| 11.12. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy | 165 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen | |
| 11.12. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11. | Tenaya Therapeutics GAAP EPS of -$0.12 beats by $0.03 | 16 | Seeking Alpha | ||
| 10.11. | Tenaya Therapeutics, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
| 10.11. | FDA puts Tenaya heart disease gene therapy clinical trial on hold | 13 | FierceBiotech | ||
| 08.11. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy | 5 | GlobeNewswire (USA) | ||
| 07.11. | FDA stoppt klinische Studie von Tenaya Therapeutics zu Herzmedikament TN-201 | 8 | Investing.com Deutsch | ||
| 07.11. | Tenaya Therapeutics falls after FDA clinical hold on heart disorder trial | 20 | Seeking Alpha |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | 0,00 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| CUREVAC | 3,536 | +4,12 % | Morgen-Update: Curevac-Aktie auf Höhenflug - Anleger feiern starkes Comeback! | ||
| MODERNA | 27,250 | -0,51 % | Nvidia Rises, Moderna and Brown-Forman Slump, and More | ||
| VALNEVA | 3,632 | +0,22 % | Morgen-Update: Valneva-Aktie explodiert - Anleger im Kaufrausch! | ||
| AMGEN | 280,45 | -0,23 % | ROUNDUP/Aktien New York Schluss: Erholung geht weiter | NEW YORK (dpa-AFX) - Die US-Börsen haben sich am Freitag weiter von ihrem jüngsten Rücksetzer erholt. Eine Jahresendrally sei nach wie vor möglich, sagte ein Investmentexperte. Es herrschte unvermindert... ► Artikel lesen | |
| NOVAVAX | 5,750 | -0,40 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 147,90 | -0,27 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,400 | +0,83 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,810 | -0,55 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,400 | -1,23 % | Bionxt Solutions Inc: Bionxt Solutions talks up sublingual thin-film product | ||
| OCUGEN | 1,185 | -0,59 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| MAINZ BIOMED | 1,190 | +3,48 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,070 | +0,58 % | Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) | ||
| INTELLIA THERAPEUTICS | 7,964 | -0,18 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| BIO-GATE | 0,790 | -3,07 % | Bio-Gate: EBITDA verbessert | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im ersten Halbjahr des Geschäftsjahres 2025 (per 31.12.) mit 3,44 Mio. Euro einen leicht unter Vorjahr... ► Artikel lesen |
TENAYA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,748 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TENAYA THERAPEUTICS INC finden Sie auf Wallstreet Online.